Piramal Pharma is trading -8.01% lower at Rs 184.80 as compared to its last closing price. Piramal Pharma has been trading in the price range of 202.05 & 181.85. Piramal Pharma has given -30.55% in this year & -18.35% in the last 5 days. Piramal Pharma has TTM P/E ratio 915.83 as compared to the sector P/E of 25.53.There are 6 analysts who have initiated coverage on Piramal Pharma. There are 4 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 3.68 Crores in its last quarter.Listed peers of Piramal Pharma include GO DIGIT GENERAL INSURANCE (-2.41%), Ola Electric Mobility (-5.31%), Piramal Pharma (-8.01%).The Mutual Fund holding in Piramal Pharma was at 11.66% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Piramal Pharma was at 31.68% in 31 Dec 2024. The FII holding has decreased from the last quarter.
Updated on Feb 15, 2025, 12:38 AM UTC
|
|
|
|
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
---|---|---|---|---|---|---|---|---|
GO DIGIT GENERAL INSURANCE | Bearish | 289.90 | -2.41 | 26,731.38 | 150.14 | 7.19 | - | - |
Ola Electric Mobility | Bearish | 60.84 | -5.31 | 25,381.14 | - | 6.22 | - | 65.30 |
Piramal Pharma | Bearish | 184.80 | -8.01 | 24,414.03 | 435.99 | 3.35 | 0.05 | 32.89 |
Sagility India | Bearish | 47.45 | -4.47 | 22,212.90 | 103.41 | 3.62 | - | 33.15 |
Concord Biotech | Bearish | 1,693.20 | -19.75 | 17,700.38 | 71.70 | 14.47 | 0.41 | 0.12 |
Meeting Date | Purpose |
---|---|
2025-01-28 | Quarterly Results |
2024-10-23 | Quarterly Results |
2024-07-26 | Quarterly Results |
2024-05-10 | Audited Results & Final Dividend |
2024-01-30 | Quarterly Results |
Piramal Pharma is trading at 184.80 as on Fri Feb 14 2025 10:28:17. This is -8.01% lower as compared to its previous closing price of 200.90.
The market capitalization of Piramal Pharma is 24414.03 Cr as on Fri Feb 14 2025 10:28:17.
The average broker rating on Piramal Pharma is Strong Buy. The breakup of analyst rating is given below -
The 52 wk high for Piramal Pharma is 307.85 whereas the 52 wk low is 114.45
Piramal Pharma can be analyzed on the following key metrics -
Piramal Pharma reported a net profit of 17.82 Cr in 2024.
The Mutual Fund Shareholding was 11.66% at the end of 31 Dec 2024.